ArticleThe World Allergy Organization journal2025
Using mobile technology to increase adherence to sublingual immunotherapy: Real-world study with a new app/web platform AllergyVax®.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Monitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform.The journal of allergy and clinical immunology. Global · 2026Article
- Advances in clinical examination techniques for allergic rhinitis: a review from traditional testing to precision diagnosis.Frontiers in allergy · 2026Review
- Digital health in allergy care: current practices, evidence, and future prospects.Frontiers in allergy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy (AIT) is a key therapeutic approach for allergic rhinitis and asthma, demonstrating the ability to modify disease progression by targeting type 2 inflammation. This study evaluates the efficacy of a mobile application (app/web platform) AllergyVax®, designed to implement a patient-centered care (PCC) strategy to increase patient engagement in the treatment. A retrospective cross-sectional analysis was conducted with 482 patients diagnosed with respiratory allergic diseases who initiated sublingual immunotherapy (SLIT). Participants were divided into 2 groups: Group A received standard information, while Group B utilized the AllergyVax® app for managing treatment. This app provided daily reminders, evaluated symptom control through standardized questionnaires, and facilitated communication between patients and healthcare providers. Results indicated a significant increase in adherence rates among app users, with 92.11% adhering to SLIT compared to 46.32% in the non-app group. The app users exhibited a 2.42 times greater likelihood of maintaining adherence and reduced dropout rates by 82%. The AllergyVax® app improved adherence across all demographics, emphasizing the importance of innovative digital tools in enhancing patient engagement and treatment outcomes. In conclusion, this study highlights the critical role of mobile technology in promoting adherence to SLIT, suggesting that integrating digital solutions into AIT can lead to better management of allergic diseases and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.